<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766853</url>
  </required_header>
  <id_info>
    <org_study_id>H-1812-128-997</org_study_id>
    <nct_id>NCT04766853</nct_id>
  </id_info>
  <brief_title>Verification of the Efficacy/Safety of the Dual Drug Delivery for Hearing Loss</brief_title>
  <official_title>Verification of the Efficacy / Safety of the Dual Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized pilot study. To verify an efficacy and safety of the&#xD;
      dual drug injectable delivery vehicle, patients who have not responded to the existing&#xD;
      standard treatment will be enrolled. Hearing test and endoscopy of tympanic membrane will be&#xD;
      conducted after intratympanic treatment for evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verification of tympanic membrane with endoscopy (Safety)</measure>
    <time_frame>within 2 weeks after intratympanic injection</time_frame>
    <description>Confirming healing time of perforation and inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmation of inflammation and drug with x-ray or CT imaging (Durability)</measure>
    <time_frame>within 2 weeks after intratympanic injection</time_frame>
    <description>Checking a time duration of drug in middle and inner ear</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valuation of hearing threshold with Pure tone audiometry (Efficacy)</measure>
    <time_frame>1 month after intratympanic injection</time_frame>
    <description>Verifying therapeutic effect of intratympanic drug delivery vehicle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Hearing Loss, Sudden</condition>
  <condition>Hearing Loss Ototoxic</condition>
  <condition>Hearing Loss, Noise-Induced</condition>
  <condition>Meniere Disease</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone+Hyaluronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 5mg/ml</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_label>Dexamethasone+Hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Dexamethasone+Hyaluronic Acid</description>
    <arm_group_label>Dexamethasone+Hyaluronic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sudden hearing loss, ototoxic hearing loss, noise-induced hearing loss, meniere's&#xD;
             disease patients with 25dB HL in pure tone audiometry&#xD;
&#xD;
          -  Patients whose hearing has not been restored after standard treatment&#xD;
&#xD;
          -  Patients do not participate in clinical trials within 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with retrocochlear lesion&#xD;
&#xD;
          -  Patients with history of hypersensitivity to the substance of this drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myung-Whan Suh</last_name>
    <phone>+821039490330</phone>
    <email>drmung@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu-Jung Hwang</last_name>
    <email>eliteyujung@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Whan Suh</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hearing loss</keyword>
  <keyword>Drug Delivery</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Intratympanic injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Meniere Disease</mesh_term>
    <mesh_term>Hearing Loss, Noise-Induced</mesh_term>
    <mesh_term>Hearing Loss, Sudden</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

